Abstract
Paraoxonase1 (PON1) gene polymorphisms were implicated as risk factors for Parkinson’s disease (PD), but the results of case-control studies that investigated these associations were controversial. In order to provide an answer to these contradictory results, a meta-analysis of all available studies relating the PON1-55M/L and PON1-192Q/R polymorphisms to the risk of developing PD was conducted. The racial descent of the populations in these studies was Caucasian and Asian. The meta-analysis revealed that there was an association of the PON1-55M allele and the risk of developing PD relative to the L allele: fixed effects pooled odds ratio (OR)=1.32 [95%CI (1.10–1.59)]. In addition, there was evidence of association for the genotypic contrast PON1-55MM+LM relative to PON1-55LL: fixed effects OR=1.50 [95%CI (1.16–1.95)]. There was no significant association between PON1-192Q/R alleles and risk of developing PD: OR=1.09 [95%CI (0.93–1.26)]. There was no evidence for an association between the genotypic contrasts of PON1-192 and development of PD. The heterogeneity between studies and the publication bias were not significant (P≥0.10) in either polymorphism. Therefore, the pooled results of the meta-analysis supported that there was an association between PON1-55M/L polymorphism and PD and that PON1-192Q/R polymorphism was unlikely to be a major risk factor for susceptibility to PD.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598–608
Akhmedova S, Anisimov S, Yakimovsky A, Schwartz E (1999) Gln→Arg 191 polymorphism of paraoxonase and Parkinson’s disease. Hum Hered 49:178–180
Akhmedova S, Yakimovsky A, Schwartz EI (2001) Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson’s disease. J Neurol Sci 184:179–182
Carmine A, Buervenich S, Sydow O, Anvret M, Olson L (2002) Further evidence for association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease. Mov Disord 17:764–766
Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101–129
Gowan J, Sinton CM, Varley AW, Wians FH, Haley RW, Munford RS (2001) Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 173:1–6
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. Br Med J 327:557–560
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski C, Furlog CE (1993) The molecular basis of human serum paraoxonase activity polymorphism. Nat Genet 3:73–76
Ioannidis JP (1998) Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. J Am Med Assoc 279:281–286
Kelada SN, Costa-Mallen P, Checkoway H, Viernes HA, Farin FM, Smith-Weller T, Franklin GM, Costa LG (2003) Paraoxonase 1 promoter and coding region polymorphisms in Parkinson’s disease. J Neurol Neurosurg Psychiatry 74:545–548
Kondo I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson’s disease. Brain Res 806:271–273
Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327:248–254
Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826
Le Couteur DG, McLean AJ, Taylor MC, Woodham BL, Board PG (1999) Pesticides and Parkinson’s disease. Biomed Pharmacother 53:122–130
Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN (1997) Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 122:265–268
Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149–157
Ntais C, Polycarpou A, Ioannidis JP (2003) Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12:120–126
SAGE (2003) Statistical Analysis for Genetic Epidemiology. Computer program package available from Statistical Solutions Ltd, Cork
Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T (2000) Variability and validity of polymorphism association studies in Parkinson’s disease. Neurology 55:533–538
Taylor MC, Le Couteur DG, Mellick GD, Board PG (2000) Paraoxonase polymorphisms, pesticide exposure and Parkinson’s disease in a Caucasian population. J Neural Transm 107:979–983
Wang J, Liu Z (2000) No association between paraoxonase 1 (PON1) gene polymorphism and susceptibility to Parkinson’s disease in a Chinese population. Mov Disord 15:1265–1267
Warner TT, Schapira AHV (2003) Genetic and environmental factors in the cause of Parkinson’s disease. Ann Neurol 53(Suppl 3):S16–S25
Weir BS (1996) Genetic data analysis II: methods for discrete population genetic data. Sinauer Associates, Sunderland
Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J (2004) Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls: meta-analysis of 43 studies. Lancet 363:689–695
Whitehead A (1997) A prospectively planned cumulative meta-analysis applied to a series of concurrent clinical trials. Stat Med 16:2901–2913
Whitehead A (2002) Meta-analysis of controlled clinical trials. Wiley, Chichester
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zintzaras, E., Hadjigeorgiou, G.M. Association of paraoxonase 1 gene polymorphisms with risk of Parkinson’s disease: a meta-analysis. J Hum Genet 49, 474–481 (2004). https://doi.org/10.1007/s10038-004-0176-x
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-004-0176-x
Keywords
This article is cited by
-
Pon1 Deficiency Promotes Trem2 Pathway–Mediated Microglial Phagocytosis and Inhibits Pro-inflammatory Cytokines Release In Vitro and In Vivo
Molecular Neurobiology (2022)
-
Meta-Analysis of the COMT Val158Met Polymorphism in Major Depressive Disorder: Effect of Ethnicity
Journal of Neuroimmune Pharmacology (2016)
-
The R219K Polymorphism on ATP-Binding Cassette Transporter A1 Gene is Associated with Coronary Heart Disease Risk in Asia Population: Evidence from a Meta-Analysis
Cell Biochemistry and Biophysics (2015)
-
A New PCR Method: One Primer Amplification of PCR-CTPP Products
Molecular Biotechnology (2012)
-
Quantitative assessment of the effect of ABCA1 R219K polymorphism on the risk of coronary heart disease
Molecular Biology Reports (2012)
